Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Effector Therapeutics Inc (EFTR)

Effector Therapeutics Inc (EFTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CenterPoint: Q2 Earnings Snapshot AP - Fri Jul 25, 2025

CenterPoint: Q2 Earnings Snapshot

EFTR : 0.0002 (unch)
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Tue Aug 9, 2022

Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as...

EFTR : 0.0002 (unch)
eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer Globe Newswire - Mon Aug 8, 2022

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of...

EFTR : 0.0002 (unch)
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity Globe Newswire - Sun Jun 5, 2022

Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new...

EFTR : 0.0002 (unch)
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting Globe Newswire - Thu May 26, 2022

Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide...

EFTR : 0.0002 (unch)
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Tue May 10, 2022

Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded development...

EFTR : 0.0002 (unch)
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire - Mon May 2, 2022

SAN DIEGO and REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering...

EFTR : 0.0002 (unch)

Barchart Exclusives

Should You Buy the Dip in United Airlines Stock? Barchart - Wed Apr 22, 3:56PM CDT
United Airlines shares sink as muted full-year guidance weighs on a strong Q1 release. But options pricing suggests the post-earnings dip in UAL stock may be an opportunity for long-term investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.